(Sharecast News) - UBS has upgraded AstraZeneca to a 'buy', citing the London-listed pharmaceutical firm's "sector-leading" drug pipeline.
In a note published on Thursday, UBS - which previously had a 'neutral' rating - said AstraZeneca had scored second among global pharma peers, based on the Swiss bank's analysis of six strategic...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE